MSMehmet Soy

Mehmet Soy

*This is an algorithmically generated author record based on publicly available information.

Mehmet Soy has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recent advances in the pathogenesis, diagnosis, and management of sarcoidosis: A comprehensive narrative review

    by Mehmet Soy, Fatma Alibaz Öner, Muhammet Emin Kutu

    Sarcoidosis is a heterogeneous multisystem disorder of unknown etiology, characterized by the formation of epithelial non-caseating granuloma. While pulmonary and intrathoracic lymph node involvement represent the primary clinical manifestations, the disease frequently affects extrathoracic organs, including the skin, eyes, brain, heart, and musculoskeletal system; cardiac and neurological involvement are critical determinants of overall prognosis. Recent advances in pathogenesis highlight a complex interplay between genetic predisposition, autoimmunity, and environmental triggers such as silica dust, mycobacteria, and Cutibacterium acnes. Clinically, pathognomonic presentations such as Löfgren’s syndrome and Heerfordt syndrome aid in rapid diagnosis, while modern imaging techniques such as 18F-FDG PET/CT and cardiac MRI have significantly improved the classic Scadding chest radiography staging by detailing extrathoracic disease activity. In addition, the rapid integration of artificial intelligent and machine learning technologies enhances diagnostic accuracy through automated image analysis, biomarker identification, and personalized disease course prediction. Current treatment strategies are focusing on risk-stratified management, shifting from traditional corticosteroids and immunosuppressants to targeted biological agents for organ-threatening diseases. A multidisciplinary strategy is essential for therapy and follow-up. Treatment does not need to be given to every patient. The decision regarding treatment should be made after a thorough multidisciplinary evaluation based on clinical, radiological, and additional findings. The main medication is corticosteroids; however, methotrexate, azathioprine, and in some instances, TNF-α blockers, along with various other biological agents, may be used.

  • Open Access

    Idiopathic inflammatory myopathies: A non-systematic review

    by Mehmet Soy, Zeynep Serra Tüzün, Tayfun Uzunaslan

    Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases that primarily affect the muscles and skin but may also involve other organs, including the lungs, heart, and joints. They are rare compared to other autoimmune inflammatory rheumatic diseases. There have been changes in their classification criteria with the recognition that numerous autoantibodies play a role in disease pathogenesis. IIMs are currently classified into five main types: Dermatomyositis, polymyositis, overlap syndromes and antisynthetase syndrome, immune-mediated necrotizing myopathy, and inclusion body myositis. Autoantibodies implicated in IIMs are categorized as myositis-specific antibodies (MSA) or myositis-associated antibodies. Each MSA is associated with specific clinical and pathological features. Identifying these antibodies during diagnosis is valuable for both the treatment and prognostic assessment. For example, anti-Mi2 positivity is associated with milder disease courses and favorable treatment responses. Anti-MDA5 positivity is closely associated with rapidly progressive interstitial lung disease. In contrast, anti-TIF1-γ and anti-NXP2 antibodies are important risk factors for the development of malignancy. Early diagnosis and treatment are crucial for disease control. Most patients respond well to corticosteroids, while methotrexate or azathioprine are commonly used as corticosteroid-sparing drugs. If necessary, more potent immunosuppressive, biological agents, and intravenous immunoglobulin can be used. In this review, we summarized the recent advances in the understanding and management of IIMs over the last 10 years.

  • Open Access

    Pulmonary Hypertension in Connective Tissue Diseases

    by Mehmet Soy, Mustafa Yıldız, Aslı Özmaden Hantal Özmaden Hantal, Tuba Çiftçi Küsbeci, İffet Doğan

    Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure >20 mmHg at rest, confirmed by right heart catheterization (RHC). The European Society of Cardiology and the European Respiratory Society (ESC/ ERS) published a new guideline in 2022 with recommendations for the classification, diagnosis, and treatment of PH. Pulmonary arterial hypertension (PAH) is a subgroup of PH and is most commonly seen together with connective tissue diseases after the idiopathic form. PAH may develop in connective tissue patients, most commonly in cases of systemic scleroderma. The presence of PAH significantly affects the quality of life and survival in connective tissue patients, especially in scleroderma. In PAH cases, early diagnosis and treatment before organ damage develops is the golden rule in treatment. Diagnosis should first be triggered by complaints such as unexplained dyspnea and syncope that develop in the presence of an underlying connective tissue disease such as scleroderma, which increases the risk of PAH and is made by RHC in the light of data obtained from examinations such as electrocardiogram, echocardiography, pulmonary function tests, and diffusing capacity for carbon monoxide. When planning treatment, pharmacological treatments are used in addition to non-pharmacological measures. Drug selection should be made by taking into account the patient’s other characteristics. Combination oral therapy with an endothelin receptor antagonist and a phosphodiesterase 5 inhibitor is often the first-line treatment in scleroderma-PAH. During follow-ups, treatment may be changed according to the patient’s clinical and laboratory data and risk analysis. For patients with functional class IV (the most severely ill patients), additional triple combination therapy consisting of a prostaglandin analog may be considered. Treatment is determined and followed according to the ERS/ESC 2022 guideline and other guidelines mostly developed in light of this guideline. Lung transplantation should not be ignored in cases resistant to these treatments. Despite current developments, the prognosis in PH cases is still poor and patients should be followed and treated in experienced centers specialized for PH.


  • Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases

    by Selda Celik, Muhammet Emin Kutu, Cengiz Bal, Burcak Karadeniz, Pamir Atagunduz, Mehmet Soy

    Letters to the Editor; Authors: S. Celik, M.E. Kutu, C. Bal, B. Karadeniz, P. Atagunduz, M. Soy

  • Open Access

    Pathogenesis and treatment of cytokine storm in COVID-19

    by Mehmet Soy, Gökhan Keser, Pamir Atagündüz

    COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.


  • A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

    by Mehmet Soy, Gökhan Keser, Pamir Atagunduz, Melek Yalçin Mutlu, Alper Gunduz, Gizem Koybaşi, Cemal Bes

    The COVID-19 pandemic has occupied the world agenda since December 2019. With no effective treatment yet, vaccination seems to be the most effective method of prevention. Recently developed vaccines have been approved for emergency use only and are currently applied to large populations. Considering both the underlying pathogenic mechanisms of autoimmune/autoinflammatory rheumatological diseases (AIIRDs) and the immunosuppressive drugs used in treatment, vaccination for COVID-19 deserves special attention in such patients. In this article, we aimed to give simple messages to the clinicians for COVID-19 vaccination in patients with AIIRDs based upon the current evidence regarding the use of other vaccines in this patient group. For this purpose, we conducted a “Pubmed search” using the following keywords: Influenza, Hepatitis B, Pneumococcal, and Shingles vaccines and the frequently used conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Likewise, an additional search was performed for the COVID-19 immunization in patients with AIIRDs and considering such drugs. In summary, patients with AIIRDs should also be vaccinated against COVID-19, preferably when disease activity is under control and when there is no concurrent infection. Low-degree immunosuppression does not appear to decrease antibody responses to vaccines. Ideally, vaccinations should be done before the initiation of any biological DMARDs. Patients receiving rituximab should be vaccinated at least 4 weeks before or 6 months after treatment. Since tofacitinib may also reduce antibody responses, especially in combination with methotrexate, it may be appropriate to discontinue this drug before vaccination and to restart after 14 days of immunization. Key points • COVID-19 vaccinations should preferably be made during remission in patients with autoimmune/autoinflammatory rheumatological diseases. • Low-degree immunosuppression may not interfere with antibody response to vaccines. • Ideally, vaccinations should be made before the initiation of any biological DMARDs. • Timing of vaccination is especially important in the case of rituximab.


  • Top Cited Papers

    Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic

    by Mehmet Soy, Pamir Atagündüz, Işık Atagündüz, Gülsan Türköz Sucak

    Hemophagocytic syndrome (HPS) or hemophagocytic lymphohistiocytosis (HLH) is an acute and rapidly progressive systemic inflammatory disorder characterized by cytopenia, excessive cytokine production, and hyperferritinemia. Common clinical manifestations of HLH are acute unremitting fever, lymphadenopathy, hepatosplenomegaly, and multiorgan failure. Due to a massive cytokine release, this clinical condition is considered as a cytokine storm syndrome. HPS has primary and acquired (secondary, reactive) forms. Its primary form is mostly seen in childhood and caused by various mutations with genetic inheritance and, therefore, is called familial HLH. Secondary HLH may be caused in the presence of an underlying disorder, that is, secondary to a malignant, infectious, or autoimmune/autoinflammatory stimulus. This paper aims to review the pathogenesis and the clinical picture of HLH, and its severe complication, the cytokine storm, with a special emphasis on the developed classification criteria sets for rheumatologists, since COVID-19 infection has clinical symptoms resembling those of the common rheumatologic conditions and possibly triggers HLH. MED-LINE/Pubmed was searched from inception to April 2020, and the following terms were used for data searching: “hemophagocytic syndrome” OR “macrophage activation syndrome” OR “hemophagocytic lymphohistiocytosis”, OR “cytokine storm”. Finally, AND “COVID-19” was included in this algorithm. The selection is restricted to the past 5 years and limited numbers of earlier key references were manually selected. Only full-text manuscripts, published in an English language peer-reviewed journal were included. Manuscript selection procedure and numbers are given in Fig. 2. Briefly, the database search with the following terms of “Hemophagocytic syndrome” OR “Macrophage activation syndrome” OR “Hemophagocytic lymphohistiocytosis” OR “Cytokine storm” yielded 6744 results from inception to April 2020. The selection is restricted to the past 5 years and only limited numbers of earlier key references were selected, and this algorithm resulted in 3080 manuscripts. The addition of (AND “COVID-19”) resulted in 115 publications of which 47 studies, together with four sections of an online book were used in the final review. No statistical method was used. HLH is triggered by genetic conditions, infections, malignancies, autoimmune-autoinflammatory diseases, and some drugs. In COVID-19 patients, secondary HLH and cytokine storm may be responsible for unexplained progressive fever, cytopenia, ARDS, neurological and renal impairment. Differentiation between the primary and secondary forms of HLH is utterly important, since primary form of HLH requires complicated treatments such as hematopoietic stem cell transplantation. Further studies addressing the performance of HScore and other recommendations in the classification of these patients is necessary.


  • Top Cited Papers

    Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

    by Mehmet Soy, Gökhan Keser, Pamir Atagündüz, Fehmi Tabak, Işık Atagündüz, Servet Kayhan

    COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-α agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.


  • Open Access

    Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study)

    by Koray Taşçılar, Rıdvan Mercan, Cemal Bes, Veli Yazısız, Barış Yılmazer, Mustafa Özmen, Şükran Erten, Soner Şenel, Ayten Yazıcı, Ömer Karadağ, et al.

    Objective: The reactivation of hepatitis B virus (HBV) infection is a well-known event in hepatitis B surface antigen (HbsAg)-positive patients receiving immunosuppressive therapy. The objective of this study was to assess the antiviral practice and course of HBV infection in inflammatory arthritis. Material and Methods: Nineteen rheumatology centers participated in this retrospective study. HbsAg-positive patients who were taking disease-modifying antirheumatic drugs and who were being tested for HBV viral load at a minimum of two different time points were included. The case report form (CRF) consisted of demographic data, rheumatic diseases, treatment profiles, transaminase levels, viral hepatitis serological markers, and HBV viral load. The reactivation of HBV was defined as the abrupt rise in HBV replication by an increase in serum HBV DNA levels in a patient with a previously inactive HBV infection. Results: In total, the data of 101 (female 50.5%) patients were included (76 patients with inactive HBV carriers and 25 patients with chronic HBV infection). The mean age of patients was 44±12 years, and the mean follow-up duration was 31±22 months. Of the 101 patients, 70 (69.3%) received antiviral treatment. HBV reactivation was detected in 13 of 76 (17.1%) patients with inactive HBV carriers. HBV reactivation was observed less frequently, not although significantly, in those patients receiving antiviral prophylaxis compared with those not receiving prophylaxis [5/41 (12.2%) vs. 8/33 (24.2%), p=0.17]. Forty-two patients (31 patients had inactive HBV carriers) were using anti-tumor necrosis factor agents. HBV reactivation was detected in 6 of the 31 (19.3%) patients. Twenty-five patients had chronic hepatitis, and five (20%) of them had not received antiviral prophylaxis. HBV viral loads were persistently elevated in 7 (28%) of 25 patients (three patients under and four patients not under antiviral treatment). Conclusion: HBV reactivation was observed in approximately 17% of patients under immunosuppressive treatments. HBV reactivation was more frequently observed in those who did not receive antiviral prophylaxis.


  • Forte prévalence de kyste pilonidal dans la spondylarthrite ankylosante

    by Mehmet Soy, Pamir Atagündüz, Cemal Bes, Aysun Aksoy, Ozan Kocakaya